الفهرس يوجد فقط 14 صفحة متاحة للعرض العام
 |  | from | 131 |  |  |
| | | from | 131 | | |
المستخلص
Background: Juvenile idiopathic arthritis (JIA) is a chronic, autoimmune, inflammatory joint disease. It is the most common rheumatic disease in children and adolescents. Treatment of patients with rheumatoid arthritis (RA) has been advanced considerably over the last two decades through earlier treatment with methotrexate (MTX), low dose glucocorticoids, other disease-modifying antirheumatic drugs (DMARDs), and new biologic agents, targeted to low disease activity or remission. Aim: To study the safety and efficacy of biological DMARDs in patients diagnosed as JIA. Setting and Design: sex months prospective study at a pediatric hospital of Cairo university. Results: There was statistically significant improvement in DAS28-ESR after 6 months of biological treatment, but improvement in DAS28-ESR after 3 months of treatment more than DAS28-ESR after 6 months. Conclusion: our findings indicate that biological DMARDs gave better response than other synthetic DMARDs in treatment of juvenile idiopathic arthritis. The onset of start of biological treatment determines the prognosis. But because of our limited finances, the biological treatment was started late in our patients who gave better response after 3months of treatment than fter 6 months of treatment